Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 4/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22489851 | 0.91 | RELA (0.36) | CA12CA14CA2CA1CA7 | |
| SCHEMBL22489870 | 0.83 | CA12 (0.45) | CA12CA14CA2CA1CA7 | |
| SCHEMBL29206820 | 0.80 | CA12 (0.46) | CA12CA14CA2CA1CA7 | |
| SCHEMBL28258459 | 0.76 | CA12 (0.46) | CA12CA14CA2CA1CA7 | |
| SCHEMBL20087370 | 0.76 | APEX1 (0.35) | CA12CA14CA2CA1CA7 | |
| SCHEMBL5179584 | 0.74 | MAOA (0.39) | CA12CA14CA2CA1CA7 | |
| SCHEMBL671558 | 0.73 | LMNA (0.39) | CA12CA14CA2CA1CA9 | |
| SCHEMBL17151036 | 0.73 | CA12 (0.44) | CA12CA14CA2CA1CA7 | |
| SCHEMBL31044412 | 0.73 | TDP1 (0.45) | CA12CA14CA2CA1CA9 | |
| SCHEMBL132540 | 0.72 | HDAC1 (0.37) | CA12CA14CA2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236055-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200308122-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308122-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | GPR119, SSTR5, FFAR3 | CA12 1897/4885CA14 1851/4885CA2 786/4885 |
| US-11236055-B2 | Non-systemic TGR5 agonists | SSTR5, GPR119, FFAR3 | CA12 1866/4885CA14 1852/4885CA2 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.